Previous studies demonstrated that targeting the DDR pathway with PARP or CHK1 inhibitors led to an accumulation of cytosolic DNA, which activated the cGAS/STING/TBK1/IRF3 pathway and, in turn, directly promoted expression of type I IFNs in SCLC (Sen et al., 2019a, 2019b). The gene discussed is TBK1; the disease is small cell lung carcinoma.